Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma

被引：0

作者：

Akula, Vinita ^{[1
]}

Chen, Lily ^{[1
]}

Acikgoz, Yusuf ^{[2
]}

Klein, Katherine ^{[1
]}

Yavuz, Betul Gok ^{[3
]}

Cevik, Lokman ^{[4
]}

Demir, Tarik ^{[5
]}

Manne, Ashish ^{[2
]}

Sahin, Ilyas ^{[6
]}

Kaseb, Ahmed ^{[7
]}

Hasanov, Elshad ^{[2
]}

机构：

[1] Univ Texas, Dept Internal Med, Hlth Sci Ctr, Houston UTHealth, Houston, TX USA

[2] Ohio State Univ, Comprehens Canc Ctr, Dept Internal Med, Div Med Oncol, Columbus, OH 43210 USA

[3] Univ Missouri, Dept Med, Columbia, MO USA

[4] Ohio State Univ, Wexner Med Ctr, Dept Pathol, Columbus, OH USA

[5] Northwestern Univ, Div Hematol & Oncol Dev Therapeut Inst, Chicago, IL USA

[6] Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL USA

[7] Univ Texas, Dept Gastrointestinal Med Oncol, MD Anderson Canc Ctr, Houston, TX USA

来源：

NPJ PRECISION ONCOLOGY | 2025年 / 9卷 / 01期

关键词：

CAMRELIZUMAB PLUS APATINIB; OPEN-LABEL; DOUBLE-BLIND; SINGLE-ARM; RECURRENCE; RESECTION; SORAFENIB; CANCER; TRIAL; HCC;

D O I：

10.1038/s41698-025-00846-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC treatment is challenging; surgical resection is the primary curative treatment for early-stage disease, but recurrence rates are high. Immune checkpoint inhibitors (ICIs) are a promising neoadjuvant treatment that can reduce recurrence rates and mortality after surgery and achieve complete/partial responses. Clinical trials provide strong evidence for the efficacy and safety of ICI monotherapy for neoadjuvant HCC treatment.

引用

页数：13

共 50 条

[21] Meta-analysis of the efficiency and safety of neoadjuvant therapy with immune checkpoint inhibitors in resectable hepatocellular carcinoma
Tuersun, Adili
Yasen, Yadikaer
Mohetaer, Munire
Hou, Guanxin
Cheng, Gang
Zhao, Xin
FRONTIERS IN MEDICINE, 2025, 11
[22] Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma
Nishida, Naoshi
Kudo, Masatoshi
CANCERS, 2020, 12 (05)
[23] Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
Qin, Ran
Jin, Tianqiang
Xu, Feng
FRONTIERS IN IMMUNOLOGY, 2023, 14
[24] Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma
Zeng, Zhu
Yang, Biao
Liao, Zheng-Yin
ONCOLOGY LETTERS, 2020, 20 (04)
[25] Primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma
Cui, Xiaowen
Ruan, Minghao
Li, Yao
Yang, Cheng
Zhou, Liuyu
Zhang, Jin
Jin, Riming
Wu, Dong
Wang, Ruoyu
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[26] Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma
Cui, Tian-ming
Liu, Yao
Wang, Jia-bei
Liu, Lian-xin
ONCOTARGETS AND THERAPY, 2020, 13 : 11725 - 11740
[27] Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
Liu, Tong
Meng, Guorui
Ma, Shihui
You, Junqi
Yu, Liang
He, Risheng
Zhao, Xudong
Cui, Yunfu
FRONTIERS IN IMMUNOLOGY, 2024, 15
[28] Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
Liu, Hao-Tian
Jiang, Meng-Jie
Deng, Zhu-Jian
Li, Le
Huang, Jian-Li
Liu, Zhen-Xiu
Li, Le-Qun
Zhong, Jian-Hong
FRONTIERS IN ONCOLOGY, 2021, 11
[29] Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
Personeni, Nicola
Pressiani, Tiziana
D'Alessio, Antonio
Prete, Maria Giuseppina
Bozzarelli, Silvia
Terracciano, Luigi
Dal Buono, Arianna
Capogreco, Antonio
Aghemo, Alessio
Lleo, Ana
Lutman, Romano Fabio
Roncalli, Massimo
Giordano, Laura
Santoro, Armando
Di Tommaso, Luca
Rimassa, Lorenza
CANCERS, 2021, 13 (22)
[30] Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
De Stefano, Nicola
Patrono, Damiano
Colli, Fabio
Rizza, Giorgia
Paraluppi, Gianluca
Romagnoli, Renato
CANCERS, 2024, 16 (13)

← 1 2 3 4 5 →